arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Anixa Biosciences Inc

ANIX
$3.44 ▲ +0.01 (+0.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
61 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Anixa Biosciences Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $115.6M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -14.4%
FCF / Share $-0.05
Trailing P/E
Price / Book 8.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

61-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-2.52M
↑ +9.8%
Operating Margin Operating profit as % of sales
-435.7%
↓ -133.3%
FCF / Share Free cash flow per share
$-0.05
↑ +34.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Cash Quality
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 61 quarters